Krystal Biotech (KRYS) Cash & Equivalents (2016 - 2026)

Krystal Biotech's Cash & Equivalents history runs 11 years deep, the most recent figure standing at $501.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 62.36% year-over-year to $501.3 million; the TTM figure through Mar 2026 stood at $501.3 million (up 62.36% YoY), while the FY2025 annual figure was $496.3 million, up 43.91% from the prior year.
• Cash & Equivalents came in at $501.3 million for Q1 2026 at Krystal Biotech, up from $496.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $501.3 million in Q1 2026 to a low of $140.7 million in Q1 2023.
• A 5-year average of $321.2 million and a median of $345.8 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 52.56% in 2022 and soared 155.08% in 2024, its largest moves.
• Krystal Biotech's Cash & Equivalents stood at $161.9 million in 2022, then jumped by 121.33% to $358.3 million in 2023, then fell by 3.76% to $344.9 million in 2024, then surged by 43.91% to $496.3 million in 2025, then climbed by 1.01% to $501.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $501.3 million, $496.3 million, and $392.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison